Ann: Neville Bassett AM appointed to PharmAust Board, page-5

Brilliant, you nailed it,,, they haven't taken on board their competitors ( other Biotechs for our investment dollars ) are out marketing them for investment dollars and investor interest....

I wouldnt mind but they have some significant obstacles to overcome,,, the market has a long memory ,,, and PAA does not seem to be aware of their market reputation ,,,,,,, the need to realise they are in recovery mode from the last Palatibility issues,, and have used up several years of time and Millions in Investor Funds....... 

Other than Epichem ,,,the next set of trials by PAA will determine the companys very existence,, I can tell that the Market will not forgive another ISSUE,, thats a PC way of saying Failure,, Juniper sold these guys down the road and didn't deliver... on our dime and time?? wake up PAA,,, your not in a bed of roses, you are under the Biotech Sector Microscope.... Results are crucial and in a timely manner......